IONIS GHR LRx

Drug Profile

IONIS GHR LRx

Alternative Names: IONIS-GHR-LRX; ISIS GHR LRx

Latest Information Update: 12 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ionis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Somatotropin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acromegaly

Most Recent Events

  • 13 Jun 2018 Ionis Pharmaceuticals plans a phase-II trial for Acromegaly in July 2018(NCT03548415)
  • 20 Feb 2018 Ionis Pharmaceuticals completes a phase I trial in Acromegaly (In volunteers) in USA (unspecified route)
  • 07 Feb 2018 Phase-I clinical trials in Acromegaly in USA (In volunteers) before February 2018 (Ionis Pharmaceuticals pipeline, February 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top